Local Field Potential Correlates of Neuropsychiatric Symptoms in Parkinson's Disease

NCT07633379 | Not Yet Recruiting

• 1 other identifier: LFP-in-PD-333102
• Study Type: observational
• Target: 20
• Locations: 2 countries
• Sites: 2

Brief Summary

This prospective observational cohort study aims to investigate whether intracranial Local Field Potentials (LFPs) recorded from implanted Deep Brain Stimulation (DBS) devices are associated with neuropsychiatric symptoms in people with Parkinson's disease (PD). The study will focus on paroxysmal anxiety, impulse control disorders, and hallucinations. Twenty participants with Parkinson's disease and an implanted Medtronic Percept DBS device will be recruited. Participants will complete behavioural and clinical assessments and will use the event-marking functionality of the DBS device to record symptom episodes over a monitoring period of approximately 120 days. Brain activity will be passively recorded during this period. The study will evaluate relationships between LFP signals, symptom occurrence, behavioural task performance, and clinical symptom severity measures. Machine learning approaches will be used to identify electrophysiological patterns associated with neuropsychiatric symptom states at an individual level. The findings may improve understanding of the neural mechanisms underlying neuropsychiatric symptoms in Parkinson's disease and support the future development of personalised adaptive neuromodulation approaches.

Conditions

PARKINSON DISEASE (Disorder)

Outcome Measures

Primary Outcomes (1)

• Identification of Local Field Potential Correlates of Neuropsychiatric Symptoms in Parkinson's Disease

  Association between intracranial Local Field Potential (LFP) recordings from the Medtronic Percept Deep Brain Stimulation device and participant-reported neuropsychiatric symptom events, including hallucinations, impulse control symptoms, and episodic anxiety. Machine learning approaches will be used to identify electrophysiological patterns associated with symptom states.

  Baseline through Day 120

Secondary Outcomes (3)

• Temporal Dynamics of Neuropsychiatric Symptoms

  Baseline through Day 120

• Association Between LFP Features and Behavioural Task Performance

  Baseline assessment at Day 0

• Association Between LFP Features and Clinical Symptom Severity Measures

  Baseline assessment at Day 0

Study Arms (1)

Parkinson's Disease Participants With Neuropsychiatric Symptoms and DBS

Participants with Parkinson's disease and co-occurring neuropsychiatric symptoms, including hallucinations, impulse control disorder, or episodic anxiety, who have previously undergone bilateral Deep Brain Stimulation implantation with a Medtronic Percept device as part of clinical care. Participants will undergo clinical and behavioural assessments and longitudinal passive recording of intracranial Local Field Potentials (LFPs) over approximately 120 days.

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with Parkinson's disease and co-occurring neuropsychiatric symptoms, including hallucinations, impulse control disorder, or episodic anxiety, who previously underwent bilateral Deep Brain Stimulation implantation with a Medtronic Percept device as part of routine clinical care at King's College Hospital or affiliated services.

You may qualify if:

• Age ≥ 18 years
• A diagnosis of Parkinson's Disease
• A diagnosis of hallucinations, impulse control disorder, or panic disorder (episodic anxiety)
• Previous bilateral DBS implantation with a Medtronic Percept device as part of clinical care

You may not qualify if:

• Non-English speakers
• \<18 years old or \>75 years old
• A history of concurrent conditions that could significantly confound the study results, such as other significant neurological condition (e.g., brain injury/infection, substance abuse) or concurrent severe psychiatric condition (e.g., schizophrenia)
• Moderate/severe Intellectual Disability or inability to understand study procedures
• Lack of capacity to consent to the study
• Currently involvement in other studies

Sponsors & Collaborators

• King's College London: lead
• Ruijin Hospital: collaborator

Study Sites (2)

Ruijin Hospital

Shanghai, China

Location

King's College London

London, England, WC2R 2LS, United Kingdom

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Central Study Contacts

Paul Shotbolt, PhD

CONTACT

+4402078365454; paul.shotbolt@kcl.ac.uk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 28, 2026
• First Posted: June 8, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): February 1, 2028
• Last Updated: June 8, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share

Locations

GB (1); CN (1)